Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Neuroblastoma
91%
High-risk Neuroblastoma
42%
Neuroblastoma Cells
40%
Difluoromethylornithine
35%
Refractory Neuroblastoma
28%
Nifurtimox
27%
Medulloblastoma
26%
Relapsed/refractory
24%
Tumor
23%
Guided Therapy
20%
Ewing Sarcoma
15%
Neuroblastoma Cell Line
15%
Long-term Survival
14%
Apoptosis Induction
14%
Tumor Growth
13%
Combination Therapy
13%
Phase I Trial
13%
Polyamines
12%
Pediatric Patients
12%
Inhibit Tumor
12%
Apoptosis
12%
Phase II Trial
12%
Cell Proliferation
11%
Ornithine Decarboxylase
11%
Xenograft Model
11%
Pediatric Oncology
11%
Synergize
11%
Cancer Research
11%
Well Tolerated
10%
Tumor mutation Burden
10%
Antitumor Activity
10%
Multiple Antibodies
10%
Poor Prognosis
10%
Cell Viability
9%
Event-free Survival
9%
Overall Survival
9%
Cytotoxicity
9%
Novel Therapeutics
8%
Chemotherapy
8%
Maintenance Therapy
8%
Childhood Cancer
8%
Pediatric Cancer
8%
Cell Death
8%
Cyclophosphamide
8%
Topotecan
8%
Tumorigenesis
8%
Standard of Care
7%
Clinical Trials
7%
Anti-GD2 Antibody
7%
Pro-apoptotic
7%
Medicine and Dentistry
Ganglioneuroblastoma
100%
Eflornithine
42%
Neoplasm
36%
Chemotherapy
23%
Diseases
21%
Medulloblastoma
20%
Genetics
18%
In Vitro
17%
Childhood Cancer
17%
Nifurtimox
16%
Adverse Event
13%
Long Term Survival
13%
Neuroblastoma Cell
12%
Tumor Progression
12%
Phase II Trials
11%
Polyamine
11%
Cancer Research
11%
Ornithine Decarboxylase
10%
Ewing Sarcoma
10%
Solid Malignant Neoplasm
10%
Pediatrics
9%
Pediatrics Patient
8%
Carcinogenesis
8%
Xenograft
8%
Maintenance Therapy
8%
Combination Therapy
8%
Clinical Trial
8%
Cyclophosphamide
8%
Topotecan
8%
Event Free Survival
8%
Overall Survival
8%
Patient with Neuroblastoma
8%
Programmed Cell Death
8%
Oral
7%
Biopsy Technique
7%
Pediatric Cancer
7%
Immunotherapy
7%
Gene Expression Profiling
6%
Cytotoxicity
6%
Treatment Option
6%
Personalized Medicine
6%
Tumor
5%
Temozolomide
5%
Oncology
5%
Histone Deacetylase
5%
Neuroblastoma Cell Line
5%
Cell Death
5%
Cell Proliferation
5%
Cell Surface
5%
Immune Evasion
5%
Pharmacology, Toxicology and Pharmaceutical Science
Neuroblastoma
97%
Neoplasm
27%
Eflornithine
26%
Medulloblastoma
20%
Polyamine
15%
Tumor Growth
13%
Chemotherapy Regimens
12%
Nifurtimox
11%
Malignant Neoplasm
10%
Phase I Trials
10%
Calcifediol
10%
Ewing Sarcoma
10%
Solid Malignant Neoplasm
9%
Combination Therapy
9%
Adverse Event
9%
Cytotoxicity
9%
Maximum Tolerated Dose
9%
Diseases
8%
Topotecan
8%
Cyclophosphamide
8%
Ornithine Decarboxylase
8%
Carcinogenesis
7%
IC50
6%
Temozolomide
6%
Cell Viability
6%
Phase II Trials
5%
Clinical Trial
5%
Caspase 3
5%
Etoposide
5%
Childhood Cancer
5%
Osteosarcoma
5%
Birabresib
5%
Polyclonal Antibody
5%
Indole
5%
Immunotherapy
5%
Isothiocyanate
5%
Romidepsin
5%
Buparlisib
5%
Stress Activated Protein Kinase
5%
Tolfenamic Acid
5%
Rapamycin
5%
Patient-Derived Organoid
5%
Vinblastine
5%
Rhabdomyosarcoma
5%
Drug Repositioning
5%
Antiangiogenic Therapy
5%
Rho Kinase
5%
Acute Myeloid Leukemia
5%
Venetoclax
5%